Rapamycin (RAPA) is found to have neuro-protective properties in various
neuroinflammatory pathologies, including brain aging. With magnetic resonance imaging …

Alzheimer's disease (AD) is the most common type of progressive neurodegenerative
disorder, and is responsible for the most common form of dementia in the elderly …

Brain edema is a major consequence of cerebral ischemia reperfusion. However, few
effective therapeutic options are available for retarding the brain edema progression after …

Rapamycin (RAPA), an inhibitor of mammalian target of rapamycin (mTOR), exhibits a high
neuroprotective action against neurodegenerative diseases in mouse models. Since …

Lipopolysaccharide (LPS)–induced encephalopathy induces neuroinflammation. Long-term
neuroinflammation is associated with aging and subsequent cognitive impairment (CI). We …

Although rapamycin can attenuate cerebral ischemia/reperfusion (I/R) injury, the potential
roles of rapamycin on cerebral I/R injury remain largely controversial. The present work aims …

The inflammatory reaction is important in secondary injury following traumatic brain injury
(TBI). Rapamycin has been demonstrated as a neuroprotective agent in a mouse model of …

Rapamycin protects mice against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-
induced loss of dopaminergic neurons, which is an established model for Parkinson's …

Rapamycin has been shown to protect against middle cerebral artery occlusion (MCAo)
induced ischemic injury. In this study, the neuroprotective effect of rapamycin on the …

Rapamycin, an mTOR inhibitor and immunosuppressive agent in clinic, has protective
effects on traumatic brain injury and neurodegenerative diseases. But, its effects on transient …